Gemox or Alkylating Agents in Neuroendocrine Tumors? The Help of O6-Methylguanine-DNA Methyltransferase (MGMT) Status? Abstract #1067

Introduction: Alkylating agents are the backbone chemotherapy in neuroendocrine tumors (NET). However, gemcitabine associated to oxaliplatine (gemox) has showed interesting activity in a small study.
Aim(s): a) to confirm this data in a larger population, b) to compare its efficacy with alkylating agents, c) to explore if O6-methylguanine-DNA methyltransferase (MGMT) status could help to choose between both types of chemotherapies.
Materials and methods: 96 patients with metastatic NET were treated with gemox (2004-2014), after a median of 2 other systemic treatments. Among these 96 patients, 57 also received an alkylating agent (ALK). Promoter gene methylation of MGMT was assessed by pyrosequencing in 23 patients treated with both chemotherapies.
Conference: 12th Annual ENETS Conference (2015)
Category: Medical treatment - Chemotherapy
Presenting Author: Anne-Sophie Dussol

To read results and conclusion, please login ...

Further abstracts you may be interested in

#748 O6-Methylguanine-DNA Methyltransferase Deficiency in Neuroendocrine Tumors and Correlation with Response to Alkylating Agents (Temozolomide, Streptozotocin, Dacarbazine)
Introduction: Low O6-methylguanine-DNA methyltransferase (MGMT) expression is predictive of response to alkylants in some tumor types.
Conference: 10th Annual ENETS Conference (2013)
Category: PRRT-Ablative therapies-Endoscopic treatment
Presenting Author: MD thomas Walter
Keywords: MGMT
#1337 O6-Methylguanine DNA Methyltransferase (MGMT) Deficiency and Response to Aranoza-Based Therapy in Patients with Neuroendocrine Tumors
Introduction: Aranoza (3-α-L-arabinopyranosyl-1-methyl-nitrosourea) – nitrosourea derivative, as STZ. O6-methylguanine DNA methyltransferase (MGMT) is an enzyme implicated in chemotherapy resistance to alkylating agents and its low levels are associated with sensitivity to them.
Conference: 13th Annual ENETS conference (2016)
Category: Medical treatment - Chemotherapy
Presenting Author: Svetlana Polozkova
#1546 O6-Methylguanine DNA Methyltransferase (MGMT) Expression by Immunochemistry May Help Predict Response to Streptozotocin-based Chemotherapy in Pancreatic Neuroendocrine Tumours
Introduction: Streptozotocin (STZ) is an alkylating agent inducing DNA damage mainly repaired by MGMT. STZ-based chemotherapy is the first line treatment of non-resectable well-differentiated PNET. As for temozolomide, tumour MGMT deficiency may predict the efficacy of STZ in PNET.
Conference: 13th Annual ENETS conference (2016)
Category: Medical treatment - Chemotherapy
Presenting Author: Dr Olivia Hentic
Authors: Hentic O, Cros J, Zappa M, Rebours V, ...
Keywords: MGMT, Streptozotocin, PFS
#1080 Evaluation of the Combination Oxaliplatin and 5-Fluorouracil or Gemcitabine in Patients with Metastatic Lung Carcinoid Tumors
Introduction: -
Conference: 12th Annual ENETS Conference (2015)
Category: Medical treatment - Chemotherapy
Presenting Author: MD, PhD Thomas Walter
Keywords: gemox, folfox, lung, carcinoid
#475 Methylguanine DNA Methyl Transferase (MGMT) Expression Predicts Response to Temozolamide in Patients with Digestive Neuroendocrine Tumors (NETs)
Introduction: Temozolomide (TEM) is an oral drug with encouraging results in pancreatic NETs (PNETs). MGMT tumor deficiency seems to be correlated with higher treatment efficacy.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Dr Olivia Hentic
Authors: Hentic O, Cros J, Rebours V, Zappa M, ...